2023
Top advances of the year: Head and neck cancer
Verma A, Burtness B. Top advances of the year: Head and neck cancer. Cancer 2023, 129: 1308-1312. PMID: 36692372, DOI: 10.1002/cncr.34654.Peer-Reviewed Original ResearchConceptsProgression-free survivalFavorable-risk patientsRisk patientsNeck cancerHuman papillomavirus-associated oropharyngeal cancerGemcitabine/cisplatin chemotherapyImmature survival dataVirus-related cancersIntermediate-risk patientsFirst-line treatmentPhase 3 trialCooperative group trialsTreatment deintensificationMetastatic headOverall survivalPostoperative therapySmoking historyOropharyngeal cancerAntibody nivolumabCisplatin chemotherapyTransoral resectionTransoral surgeryNasopharyngeal cancerGroup trialsGy radiation
2017
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.
Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. Journal Of The National Comprehensive Cancer Network 2017, 15: 761-770. PMID: 28596256, DOI: 10.6004/jnccn.2017.0101.Peer-Reviewed Original ResearchConceptsNeck cancerHuman papillomavirus-associated oropharyngeal cancerNCCN Clinical Practice GuidelinesNCCN Guidelines InsightsClinical practice guidelinesTreatment of patientsImmunotherapy agentsOccult primaryOropharyngeal cancerMost recent recommendationsTreatment recommendationsMaxillary sinusPractice guidelinesOral cavityCancerRecent recommendationsSalivary glandsHeadPatientsSinusRecommendationsRecurrentNeckOncologyPharynx